A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

摘要

We conducted a phase I study combining oxaliplatin with cytarabine and fludarabine for patients with relapsed or refractory AML. Oxaliplatin 30 mg/m(2)/d on days 1 to 4, fludarabine 30 mg/m(2), and cytarabine 500 mg/m(2) on days 2 to 6 was the MTD. Of 27 patients who were treated, 3 had a complete remission and 2 patients had complete remission without platelet recovery.